augusti 18, 2021

Ectin Research AB submits Clinical Trial Application for phase I/II study into metastatic urothelial bladder cancer

Ectin Research has submitted a Clinical Trial Application (CTA) to the Swedish Medical Products Agency for its phase I / II study with MFA-370. The study aims to evaluate MFA-370 in terms of its safety and tolerability, as well as to evaluate its clinical treatment effect in patients with metastatic urothelial bladder cancer. Ectin Research plans to submit additional CTAs in two other European countries.

The company plans to initiate the phase I part of the planned clinical phase I / II study during the end of 2021. Phase I will consist of a study of approximately 10 patients with metastatic urothelial bladder cancer in Sweden, where the focus is to study MFA-370 from a safety and tolerability point of view and determine the recommended dose for phase II.

Following approval of phase I results from the Medical Products Agency, and providing the necessary capital has been secured, Ectin Research plans to start the phase II part of the study in Sweden and two other countries in Europe, with another 30 patients with metastatic urothelial bladder cancer, to statistically evaluate MFA-370’s clinical treatment effect on patients. The Chief Investigator for the study is Professor Anders Ullén, its sponsor Ectin Research. The study will be carried out in collaboration with Karolinska University Hospital in Solna.

CEO Anna Sjöblom-Hallén: “This CTA is a significant step forward for us in the development of MFA-370. Together with our experienced partners, the contract research organization LINK Medical Research and Professor Anders Ullén, we have a fantastic study team for the continued development of a safer and hopefully more effective treatment for patients with metastatic urothelial bladder cancer.”

For further information please contact:

Anna Sjöblom-Hallén, CEO

Mob: +46 734 30 93 30

About Ectin Research AB

Ectin Research AB pharmaceutical company is developing a novel treatment that eliminates cancer tumors. Its drug candidate MFA-370 will first be trialled for the treatment of metastatic bladder cancer. MFA-370 consists of two existing drugs that have already undergone large-scale clinical trials and are currently widely used in other indications. In preclinical studies MFA-370 has achieved successful results for the treatment of metastatic bladder cancer, and has also shown promising potential in other cancers such as breast, colorectal and prostate cancer cells.